FDA gives Amneal tentative nod for generic Xifaxin
Generic Xifaxin is indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and irritable bowel syndrome with diarrhea.
The Food and Drug Administration has tentatively approved Amneal’s rifaximin, which is a generic of Bausch Health's Xifaxin, per a report on MSN, which referenced Axios.
Generic Xifaxin is indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and for irritable bowel syndrome with diarrhea.
[Related: Bausch Health files patent lawsuit against Amneal over generic Xifaxan]
In April 2024, DSN reported that Bausch sued Amneal to prevent the launch of rifaximin.